Recent Posts
- Equitable Remedies not in the Program for Rovi Guides
- Overbreadth is in the Eye of the Beholder – The Federal Court’s Overbreadth Analysis in Rovi #2
- FCA finds that data protection does not prevent a competing amifampridine product
- Federal Court takes Rovi’s IPTV patents off the air
- Relief from the implied undertaking required before varying a confidentiality order
- Infringers held accountable with the springboard profits and accounting for profits remedies
- Third Time’s a Charm: Tadalafil Use Patent Invalidated in Summary Trial
- Norwich Orders are not a Second Stab at Discovery
- Re-Examination Board affirms validity of Teva’s Copaxone patent
- Slips of the pen do not restore Janssen’s Zytiga Monopoly